ADVERTISEMENT



Google       

Home -> Law Blog Directory -> Patent Law Blogs -> Patent Docs

OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense

Find a Local Lawyer

Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402

Bookmark

Patent Law

: Patent Docs

The Risk of Biogenerics

By Donald Zuhn, Kevin Noonan, Chris Singer, Sherri Oslick, and Jason Derry

ADVERTISEMENTS
By Kevin E. Noonan -- Follow-on biologic drugs, or biosimilars as they are called in Europe, are once again the subject of attempts by Congress to provide a regulatory pathway for approval. Currently, these drugs are not regulated by the Food, Drug and Cosmetic Act and hence not subject to the provisions of the Hatch-Waxman Act that promote generic versions of small molecule drugs. In this Congress, as in the last Congress, several bills have been introduced to "correct" this situation and provide a means for regulatory approval of generic versions of biologic drugs. A good deal of the debate...

Full post as published by Patent Docs on July 16, 2009 (boomark / email).

Bloggers, promote your law blog by nominating your blog for inclusion in USLaw.com's Law Blog Directory and RSS Reader. Benefits described.
Lawsuits and Settlements

Related Searches

























































































































US Law
#1 Online Legal Resource













Your Blog Subscriptions
Subscribe to blogs

10,000+ Law Job Listings
Lawyer . Police . Paralegal . Etc
Earn a law-related degree
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.


Practice Area
Zip Code:

Contact a Lawyer Now!






0.003 secs (from cache 10/31/26 10:08:43)